Recent discussions on X about AngioDynamics (ANGO) have centered around a high-profile sale of stock by a U.S. Congress member, sparking curiosity and debate among investors. The transaction, reportedly valued between $2,002 and $30,000, has raised questions about potential insider knowledge or political influence, given the individual's role in a key oversight committee. This news has fueled intense speculation about the stock's future trajectory.
Additionally, positive developments such as the enrollment of the first patient in the AMBITION BTK Trial for critical limb ischemia and the publication of promising results from the PRESERVE study using the NanoKnife System have also gained traction on the platform. These milestones are seen by some as potential catalysts for growth, though opinions remain mixed on their immediate impact. The blend of political and clinical updates keeps the conversation around ANGO dynamic and multifaceted.
Note: This discussion summary was generated from an AI condensation of post data.
AngioDynamics Congressional Stock Trading
Members of Congress have traded $ANGO stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by members of Congress over the last 6 months:
- REPRESENTATIVE DEBBIE WASSERMAN SCHULTZ has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/27 and 1 sale worth up to $15,000 on 07/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AngioDynamics Hedge Fund Activity
We have seen 75 institutional investors add shares of AngioDynamics stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,222,000 shares (+140.1%) to their portfolio in Q1 2025, for an estimated $11,474,580
- POINT72 ASSET MANAGEMENT, L.P. added 928,657 shares (+inf%) to their portfolio in Q1 2025, for an estimated $8,720,089
- MILLENNIUM MANAGEMENT LLC removed 922,996 shares (-42.7%) from their portfolio in Q1 2025, for an estimated $8,666,932
- BASTION ASSET MANAGEMENT INC. added 654,826 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,148,816
- CITADEL ADVISORS LLC removed 612,910 shares (-75.1%) from their portfolio in Q1 2025, for an estimated $5,755,224
- PIER CAPITAL, LLC added 493,991 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,638,575
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 483,049 shares (-92.5%) from their portfolio in Q1 2025, for an estimated $4,535,830
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AngioDynamics Government Contracts
We have seen $100,125 of award payments to $ANGO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AngioDynamics Analyst Ratings
Wall Street analysts have issued reports on $ANGO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/16/2025
- Lake Street issued a "Buy" rating on 07/16/2025
To track analyst ratings and price targets for AngioDynamics, check out Quiver Quantitative's $ANGO forecast page.
AngioDynamics Price Targets
Multiple analysts have issued price targets for $ANGO recently. We have seen 3 analysts offer price targets for $ANGO in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- William Plovanic from Canaccord Genuity set a target price of $17.0 on 07/16/2025
- Frank Takkinen from Lake Street set a target price of $24.0 on 07/16/2025
- Yi Chen from HC Wainwright & Co. set a target price of $16.0 on 07/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
